Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

581 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Oral repeated-dose toxicity studies of coenzyme Q10 in beagle dogs.
Yerramilli-Rao P, Beal MF, Watanabe D, Kieburtz K, Blieck EA, Kitano M, Hosoe K, Funahashi I, Cudkowicz ME. Yerramilli-Rao P, et al. Among authors: beal mf. Int J Toxicol. 2012 Jan-Feb;31(1):58-69. doi: 10.1177/1091581811425256. Epub 2012 Jan 20. Int J Toxicol. 2012. PMID: 22267890 Free PMC article.
Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS.
Ferrante KL, Shefner J, Zhang H, Betensky R, O'Brien M, Yu H, Fantasia M, Taft J, Beal MF, Traynor B, Newhall K, Donofrio P, Caress J, Ashburn C, Freiberg B, O'Neill C, Paladenech C, Walker T, Pestronk A, Abrams B, Florence J, Renna R, Schierbecker J, Malkus B, Cudkowicz M. Ferrante KL, et al. Among authors: beal mf. Neurology. 2005 Dec 13;65(11):1834-6. doi: 10.1212/01.wnl.0000187070.35365.d7. Neurology. 2005. PMID: 16344537 Clinical Trial.
A randomized study of the bioavailability of different formulations of coenzyme Q(10) (ubiquinone).
Constantinescu R, McDermott MP, Dicenzo R, de Blieck EA, Hyson HC, Beal MF, Bednarczyk EM, Bogdanov M, Metakis LJ, Browne SE, Lorenzo BJ, Ravina B, Kieburtz K. Constantinescu R, et al. Among authors: beal mf. J Clin Pharmacol. 2007 Dec;47(12):1580-6. doi: 10.1177/0091270007307571. Epub 2007 Oct 9. J Clin Pharmacol. 2007. PMID: 17925590 Clinical Trial. No abstract available.
Safety and tolerability of high-dosage coenzyme Q10 in Huntington's disease and healthy subjects.
Huntington Study Group Pre2CARE Investigators; Hyson HC, Kieburtz K, Shoulson I, McDermott M, Ravina B, de Blieck EA, Cudkowicz ME, Ferrante RJ, Como P, Frank S, Zimmerman C, Cudkowicz ME, Ferrante K, Newhall K, Jennings D, Kelsey T, Walker F, Hunt V, Daigneault S, Goldstein M, Weber J, Watts A, Beal MF, Browne SE, Metakis LJ. Huntington Study Group Pre2CARE Investigators, et al. Among authors: beal mf. Mov Disord. 2010 Sep 15;25(12):1924-8. doi: 10.1002/mds.22408. Mov Disord. 2010. PMID: 20669312
Riluzole therapy in Huntington's disease (HD).
Rosas HD, Koroshetz WJ, Jenkins BG, Chen YI, Hayden DL, Beal MF, Cudkowicz ME. Rosas HD, et al. Among authors: beal mf. Mov Disord. 1999 Mar;14(2):326-30. doi: 10.1002/1531-8257(199903)14:2<326::aid-mds1019>3.0.co;2-q. Mov Disord. 1999. PMID: 10091628 Clinical Trial.
Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline.
Shults CW, Oakes D, Kieburtz K, Beal MF, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, Lew M; Parkinson Study Group. Shults CW, et al. Among authors: beal mf. Arch Neurol. 2002 Oct;59(10):1541-50. doi: 10.1001/archneur.59.10.1541. Arch Neurol. 2002. PMID: 12374491 Clinical Trial.
Measuring the effects of therapy in Parkinson disease.
Shults CW, Haas R, Oakes D, Kieburtz K, Plumb S, Shoulson I, Beal MF, Juncos J, Nutt J. Shults CW, et al. Among authors: beal mf. JAMA. 2004 May 26;291(20):2430-1; author reply 2431. doi: 10.1001/jama.291.20.2430-b. JAMA. 2004. PMID: 15161889 No abstract available.
581 results